EirGen Pharma Product EIR-116 receives first Regulatory Approval

EirGen Pharma are pleased to announce that Eir-116, a product which was developed as a treatment for chronic (long-term) hepatitis B has received its first regulatory approval. We now look forward to working towards commercialising this product.